Compare HHS & XGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HHS | XGN |
|---|---|---|
| Founded | 1923 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Advertising | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.7M | 110.7M |
| IPO Year | 1994 | 2014 |
| Metric | HHS | XGN |
|---|---|---|
| Price | $4.62 | $8.74 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $8.86 |
| AVG Volume (30 Days) | 119.6K | ★ 226.3K |
| Earning Date | 05-14-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 97.35 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $159,570,000.00 | N/A |
| Revenue This Year | N/A | $8.12 |
| Revenue Next Year | N/A | $13.00 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.00 | $2.59 |
| 52 Week High | $4.67 | $12.23 |
| Indicator | HHS | XGN |
|---|---|---|
| Relative Strength Index (RSI) | 73.22 | 74.71 |
| Support Level | $4.14 | $4.08 |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 0.12 | 0.39 |
| MACD | -0.02 | 0.08 |
| Stochastic Oscillator | 90.57 | 95.98 |
Harte-Hanks Inc is a customer experience company. The company operates three business segments: Revenue Solutions; Customer Care; and Fulfillment & Logistics Services. It derives maximum revenue from Fulfillment & Logistics Services segment. The Fulfillment & Logistics Services segment includes printing, lettershop, advanced mail optimization (including commingling services), logistics and transportation optimization, monitoring and tracking, to support traditional and specialized mailings. The company has a geographic presence in the United States and Other countries. The majority of the revenue is earned from the United States.
Exagen Inc is a medical technology company focused on the design, development and commercialization of diagnostic testing products under its AVISE brand. These products are used for the differential diagnosis, prognosis, and monitoring of rheumatic, autoimmune, and related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). The company operates in one operating segment. The majority of the company's revenue is derived from sales of its testing products.